Based on the Maui Derm 2018 presentation by Bruce E. Strober, MD, PhD, Professor and Chair, University of Connecticut Health Center, Department of Dermatology, Farmington, Connecticut Article by Jo Ann LeQuang and the Journal of Clinical and Aesthetic Dermatology Four significant studies emerge when perusing the new data from 2017, all of which can help […]
By Ted Rosen, MD The year 2017 saw many new drugs and devices introduced that show considerable promise for dermatology patients. A fast round-up of what was approved in 2017 (including one December 2016 entry) appears in Table 1. Table 1. Drug Brand Approval Date Indication/Area What’s New Crisaborole Eucrisa® 12/14/16 Atopic dermatitis Good safety […]
By Lawrence F. Eichenfield, MD Restaurants do it all of the time—something changes and the restaurant must understand the change, adapt to it, and make changes to its system. Changes may seem unimportant—a decrease in local foot traffic, changes in customer preferences for certain foods—but they can impact business. When the change is well managed, […]
By Jonathan I. Silverberg, MD, PhD, MPH The global prevalence of atopic dermatitis (AD) has been estimated at about 15% to 20% in pediatric and 1% to 10% of adult populations. The prevalence has increased in the past few decades in many regions. It was thought that AD prevalence has increased primarily in the developed […]
Cutaneous tolerability of a novel topical minocycline gel for the treatment of rosacea Presenters: Bhatia N1, Ahmadyar M1, Hansra H2, Del Rosso J3, Baldwin H4, Daniels AM5 Affiliations: 1Therapeutics Clinical Research, San Diego, CA; 2BioPharmX, Inc., Menlo Park, CA; 3JDR Dermatology Research, LLC, Las Vegas, NV; 4The Acne Treatment and Research Center, Morristown, NJ Background/Objective: […]
Concurrent administration of ivermectin 1% cream with brimonidine 0.33% gel improves efficacy and tolerability in treatment of moderate-to-severe rosacea Presenters: Gold LS1, Papp K2, Lynde C3, Lain E4, Gooderham M5, Johnson S6, Kerrouche N7, Schäfer G8 Affiliations: 1Department of Dermatology, Henry Ford Medical Center, Detroit, MI; 2K. Papp Clinical Research, Probity Medical Research, Waterloo, ON, […]
Secukinumab achievement of psoriatic arthritis disease activity score- (PASDAS) related remission: two-year results from a Phase III study Presenters: Coates LC1, Gladman DD2, Nash P3, Fitzgerald O4, Kavanaugh A5, Rasouliyan L6, Pricop L7, Ding K7, Gaillez C8 (on behalf of the FUTURE 2 Study Group) Affiliations: 1Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University […]
Radiographic progression of structural joint damage in patients with active psoriatic arthritis treated with ixekizumab over 52 weeks Presenters: van der Heijde D1, Okada M2, Lee C3, Shuler CL3, Rathmann S3, Amato D3, Lin CY3, and Mease P4 Affiliations: 1Leiden University Medical Centre, Leiden, the Netherlands; 2St. Luke’s International Hospital, Tokyo, Japan; 3Eli Lilly and […]
Secukinumab for the treatment of scalp, nail, and palmoplantar psoriasis Presenters: Hawkes JE1,2, Lebwohl M2, Elewski B3, Kircik L2,4, Reich K5, Muscianisi E6, Gottlieb A7 Affiliations: 1The Laboratory for Investigative Dermatology, The Rockefeller University, New York, NY; 2Icahn School of Medicine at Mount Sinai, New York, NY; 3University of Alabama, Birmingham, AL; 4Indiana University School […]
Secukinumab is superior to ustekinumab in clearing skin of patients with moderate-to-severe plaque psoriasis: CLARITY, a randomized, controlled, Phase IIIb trial Presenters: Bagel J1, Nia J2, Hashim P2, Patekar M3, de Vera A3, Hugot S3, Sheng K4, Xia S5, Muscianisi E4, Blauvelt A6, Lebwohl M2 Affiliations: 1Psoriasis Treatment Center of Central New Jersey, East Windsor, […]
Administrative Office
Maui Derm
161 Wailea Ike Place, Suite A-104
Kihei, HI 96753
Stay Connected
Sign up to receive updates about upcoming meetings.